Raymond James Trust N.A. lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 2.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 71,470 shares of the company’s stock after selling 1,863 shares during the quarter. Raymond James Trust N.A.’s holdings in AstraZeneca were worth $4,722,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in AZN. Carnegie Capital Asset Management LLC raised its position in AstraZeneca by 6.0% in the second quarter. Carnegie Capital Asset Management LLC now owns 17,734 shares of the company’s stock valued at $1,062,000 after purchasing an additional 997 shares during the period. Mount Yale Investment Advisors LLC grew its position in AstraZeneca by 1.6% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 27,470 shares of the company’s stock worth $1,822,000 after purchasing an additional 440 shares in the last quarter. Moneta Group Investment Advisors LLC purchased a new position in shares of AstraZeneca during the 1st quarter valued at $218,000. Diversified Trust Co lifted its stake in shares of AstraZeneca by 14.0% in the 1st quarter. Diversified Trust Co now owns 4,550 shares of the company’s stock valued at $302,000 after purchasing an additional 560 shares during the last quarter. Finally, West Family Investments Inc. lifted its position in AstraZeneca by 3.3% during the 1st quarter. West Family Investments Inc. now owns 17,131 shares of the company’s stock worth $1,136,000 after acquiring an additional 552 shares during the last quarter. Hedge funds and other institutional investors own 21.55% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. UBS Group cut shares of AstraZeneca from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 14th. TheStreet lowered shares of AstraZeneca from a “b-” rating to a “c” rating in a research note on Tuesday, August 30th. Citigroup lifted their target price on shares of AstraZeneca from £105 ($126.87) to £130 ($157.08) in a report on Tuesday, July 12th. AlphaValue raised shares of AstraZeneca to a “reduce” rating in a report on Monday, August 22nd. Finally, Credit Suisse Group cut shares of AstraZeneca from an “outperform” rating to a “neutral” rating in a research report on Thursday, September 15th. One analyst has rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, AstraZeneca has a consensus rating of “Hold” and a consensus price target of $8,840.50.
AstraZeneca Stock Down 0.2 %
AstraZeneca Cuts Dividend
The company also recently announced a semi-annual dividend, which was paid on Monday, September 12th. Investors of record on Friday, August 12th were paid a dividend of $0.465 per share. This represents a yield of 2.2%. The ex-dividend date was Thursday, August 11th. AstraZeneca’s payout ratio is -221.95%.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.